These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640 [TBL] [Abstract][Full Text] [Related]
9. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Heilmann E; Costacurta F; Geley S; Mogadashi SA; Volland A; Rupp B; Harris RS; von Laer D Commun Biol; 2022 Apr; 5(1):391. PubMed ID: 35478219 [TBL] [Abstract][Full Text] [Related]
10. Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376. Lin C; Zhu Z; Jiang H; Zou X; Zeng X; Wang J; Zeng P; Li W; Zhou X; Zhang J; Wang Q; Li J J Mol Biol; 2024 Mar; 436(6):168474. PubMed ID: 38311236 [TBL] [Abstract][Full Text] [Related]
11. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
12. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743 [TBL] [Abstract][Full Text] [Related]
13. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Abdizadeh R; Hadizadeh F; Abdizadeh T Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728 [TBL] [Abstract][Full Text] [Related]
14. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro). Rothan HA; Teoh TC Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543 [TBL] [Abstract][Full Text] [Related]
15. Identification of Novel Drug Candidates for the Inhibition of Catalytic Cleavage Activity of Coronavirus 3CL-like Protease Enzyme. Gurung AB; Al-Anazi KM; Ali MA; Lee J; Farah MA Curr Pharm Biotechnol; 2022; 23(7):959-969. PubMed ID: 34097590 [TBL] [Abstract][Full Text] [Related]
16. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity. Morita T; Miyakawa K; Jeremiah SS; Yamaoka Y; Sada M; Kuniyoshi T; Yang J; Kimura H; Ryo A Viruses; 2021 Aug; 13(8):. PubMed ID: 34452533 [TBL] [Abstract][Full Text] [Related]
17. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
18. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants. Pérez-Vargas J; Worrall LJ; Olmstead AD; Ton AT; Lee J; Villanueva I; Thompson CAH; Dudek S; Ennis S; Smith JR; Shapira T; De Guzman J; Gang S; Ban F; Vuckovic M; Bielecki M; Kovacic S; Kenward C; Hong CY; Gordon DG; Levett PN; Krajden M; Leduc R; Boudreault PL; Niikura M; Paetzel M; Young RN; Cherkasov A; Strynadka NCJ; Jean F Emerg Microbes Infect; 2023 Dec; 12(2):2246594. PubMed ID: 37555275 [TBL] [Abstract][Full Text] [Related]
20. The SARS-CoV-2 main protease doesn't induce cell death in human cells in vitro. Komissarov A; Karaseva M; Roschina M; Kostrov S; Demidyuk I PLoS One; 2022; 17(5):e0266015. PubMed ID: 35609027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]